MA37519A1 - Composés et compositions pour inhiber l'activité d'abl1, abl2 et bcr-abl1 - Google Patents

Composés et compositions pour inhiber l'activité d'abl1, abl2 et bcr-abl1

Info

Publication number
MA37519A1
MA37519A1 MA37519A MA37519A MA37519A1 MA 37519 A1 MA37519 A1 MA 37519A1 MA 37519 A MA37519 A MA 37519A MA 37519 A MA37519 A MA 37519A MA 37519 A1 MA37519 A1 MA 37519A1
Authority
MA
Morocco
Prior art keywords
abl1
compounds
abl2
bcr
inhibiting
Prior art date
Application number
MA37519A
Other languages
Arabic (ar)
English (en)
Other versions
MA37519B1 (fr
Inventor
Pascal Furet
Stephanie Kay Dodd
Robert Martin Grotzfeld
Wolfgang Jahnke
Darryl Brynley Jones
Paul Manley
Andreas Marzinzik
Xavier Francois Andre Pelle
Bahaa Salem
Joseph Schoepfer
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48670630&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA37519(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA37519A1 publication Critical patent/MA37519A1/fr
Publication of MA37519B1 publication Critical patent/MA37519B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/576—Six-membered rings
    • C07F9/58—Pyridine rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

La présente invention concerne des composés de formule (i) : dans laquelle y, y
MA37519A 2012-05-15 2013-05-09 Composés et compositions pour inhiber l'activité d'abl1, abl2 et bcr-abl1 MA37519B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261647174P 2012-05-15 2012-05-15
US201361790967P 2013-03-15 2013-03-15
PCT/IB2013/053768 WO2013171639A1 (fr) 2012-05-15 2013-05-09 Composés et compositions pour inhiber l'activité d'abl1, abl2 et bcr-abl1

Publications (2)

Publication Number Publication Date
MA37519A1 true MA37519A1 (fr) 2016-06-30
MA37519B1 MA37519B1 (fr) 2017-03-31

Family

ID=48670630

Family Applications (1)

Application Number Title Priority Date Filing Date
MA37519A MA37519B1 (fr) 2012-05-15 2013-05-09 Composés et compositions pour inhiber l'activité d'abl1, abl2 et bcr-abl1

Country Status (50)

Country Link
US (2) US8829195B2 (fr)
EP (1) EP2861579B9 (fr)
JP (1) JP6078639B2 (fr)
KR (1) KR102091893B1 (fr)
CN (1) CN104302638B (fr)
AP (1) AP3613A (fr)
AR (1) AR091063A1 (fr)
AU (1) AU2013261127B2 (fr)
BR (1) BR112014026383B1 (fr)
CA (1) CA2868958C (fr)
CL (1) CL2014002757A1 (fr)
CO (1) CO7131380A2 (fr)
CR (1) CR20140519A (fr)
CU (1) CU24265B1 (fr)
CY (2) CY1120235T1 (fr)
DK (1) DK2861579T5 (fr)
DO (1) DOP2014000256A (fr)
EA (1) EA024391B1 (fr)
ES (1) ES2670601T3 (fr)
FR (1) FR22C1053I2 (fr)
GE (1) GEP201606532B (fr)
GT (1) GT201400253A (fr)
HK (1) HK1203495A1 (fr)
HR (1) HRP20180695T1 (fr)
HU (2) HUE039138T2 (fr)
IL (1) IL235566A (fr)
JO (1) JO3453B1 (fr)
LT (2) LT2861579T (fr)
MA (1) MA37519B1 (fr)
ME (1) ME03095B (fr)
MX (1) MX359014B (fr)
MY (1) MY169377A (fr)
NL (1) NL301201I2 (fr)
NO (1) NO2022043I1 (fr)
NZ (1) NZ701626A (fr)
PE (3) PE20150669A1 (fr)
PH (1) PH12014502531B1 (fr)
PL (1) PL2861579T3 (fr)
PT (1) PT2861579T (fr)
RS (1) RS57177B1 (fr)
SG (1) SG11201407152XA (fr)
SI (1) SI2861579T1 (fr)
SV (1) SV2014004850A (fr)
TN (1) TN2014000427A1 (fr)
TR (1) TR201807023T4 (fr)
TW (1) TWI560183B (fr)
UA (1) UA113208C2 (fr)
UY (1) UY34811A (fr)
WO (1) WO2013171639A1 (fr)
ZA (1) ZA201407065B (fr)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20200127273A (ko) 2012-04-26 2020-11-10 브리스톨-마이어스 스큅 컴퍼니 혈소판 응집을 치료하기 위한 프로테아제 활성화 수용체 4 (par4) 억제제로서의 이미다조티아디아졸 및 이미다조피라진 유도체
MX2014013373A (es) * 2012-05-15 2015-08-14 Novartis Ag Derivados de benzamida para inhibir la actividad de abl1, abl2 y bcr-abl1.
CA2868958C (fr) * 2012-05-15 2020-09-01 Novartis Ag Composes et compositions pour inhiber l'activite d'abl1, abl2 et bcr-abl1
JP6080947B2 (ja) 2012-05-15 2017-02-15 ノバルティス アーゲー Ａｂｌ１、ａｂｌ２およびｂｃｒ−ａｂｌ１の活性を阻害するための化合物および組成物
WO2013171642A1 (fr) * 2012-05-15 2013-11-21 Novartis Ag Dérivés de benzamide pour inhiber l'activité d'abl1, d'abl2 et de bcr-abl2
TWI568722B (zh) 2012-06-15 2017-02-01 葛蘭馬克製藥公司 作爲ｍＰＧＥＳ－１抑制劑之三唑酮化合物
WO2014110574A1 (fr) 2013-01-14 2014-07-17 Incyte Corporation Composés de carboxamide aromatique bicyclique utiles comme inhibiteurs de pim kinase
ME03780B (fr) 2013-01-15 2021-04-20 Incyte Holdings Corp Dérivés de thiazolecarboxamide et pyridinecarboxamide et leur utilisation comme inhibiteurs des kinases pim
PE20160532A1 (es) 2013-08-23 2016-05-21 Incyte Corp Compuesto de carboxamida de furo y tienopiridina utiles como inhibidores de cinasas pim
US9682931B2 (en) * 2013-11-01 2017-06-20 Ube Industries, Ltd. Aryloyl(oxy or amino)pentafluorosulfanylbenzene compound, pharmaceutically acceptable salt thereof, and prodrugs thereof
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
EP3105238A4 (fr) 2014-02-13 2017-11-08 Ligand Pharmaceuticals, Inc. Composés de promédicaments et leurs utilisations
CU24481B1 (es) 2014-03-14 2020-03-04 Immutep Sas Moléculas de anticuerpo que se unen a lag-3
WO2016003812A1 (fr) 2014-07-02 2016-01-07 Ligand Pharmaceuticals, Inc. Composés de promédicaments et leurs utilisations
US9580418B2 (en) 2014-07-14 2017-02-28 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
WO2016010897A1 (fr) 2014-07-14 2016-01-21 Incyte Corporation Composés carboxamide hétéroaromatiques bicycliques utiles en tant qu'inhibiteurs de kinases pim
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
CR20170143A (es) 2014-10-14 2017-06-19 Dana Farber Cancer Inst Inc Moléculas de anticuerpo que se unen a pd-l1 y usos de las mismas
CN104478911A (zh) * 2014-12-19 2015-04-01 成都安斯利生物医药有限公司 一种制备3-三氟甲基吡咯硼酸的方法
WO2016100882A1 (fr) 2014-12-19 2016-06-23 Novartis Ag Polythérapies
EP3789027A1 (fr) * 2015-01-13 2021-03-10 Kyoto University Bosutinib, sunitinib, tivozanib, imatinib, nilotinib, rebastinib ou bafetinib pour la prévention et/ou le traitement de la sclérose latérale amyotrophique
TN2017000375A1 (en) 2015-03-10 2019-01-16 Aduro Biotech Inc Compositions and methods for activating "stimulator of interferon gene" -dependent signalling
US9540347B2 (en) 2015-05-29 2017-01-10 Incyte Corporation Pyridineamine compounds useful as Pim kinase inhibitors
WO2017019896A1 (fr) 2015-07-29 2017-02-02 Novartis Ag Traitements combinés comprenant des molécules d'anticorps qui se lient à pd-1
PT3317301T (pt) 2015-07-29 2021-07-09 Novartis Ag Terapias de associação compreendendo moléculas de anticorpo contra lag-3
US20180207273A1 (en) 2015-07-29 2018-07-26 Novartis Ag Combination therapies comprising antibody molecules to tim-3
TWI734699B (zh) 2015-09-09 2021-08-01 美商英塞特公司 Ｐｉｍ激酶抑制劑之鹽
TW201718546A (zh) 2015-10-02 2017-06-01 英塞特公司 適用作pim激酶抑制劑之雜環化合物
SG11201803520PA (en) 2015-11-03 2018-05-30 Janssen Biotech Inc Antibodies specifically binding pd-1 and their uses
AU2016369537B2 (en) 2015-12-17 2024-03-14 Novartis Ag Antibody molecules to PD-1 and uses thereof
US9931342B2 (en) 2016-02-02 2018-04-03 Duke University Compositions and methods for the treatment of cancer
EP3448852A4 (fr) * 2016-04-29 2019-04-10 Astar Biotech LLC Nouveaux composés hétérocycliques comme inhibiteurs de la tyrosine kinase bcr-abl
WO2018009466A1 (fr) 2016-07-05 2018-01-11 Aduro Biotech, Inc. Composés dinucléotidiques cycliques d'acide nucléique bloqué et leurs utilisations
WO2018060843A1 (fr) * 2016-09-27 2018-04-05 Novartis Ag Systèmes tensioactifs pour la cristallisation de composés organiques
US20190240176A1 (en) * 2016-10-26 2019-08-08 The University Of Georgia Research Foundation, Inc. Methods of treatment for myeloid leukemia
JP7234128B2 (ja) * 2017-03-15 2023-03-07 サン・ファーマ・アドバンスド・リサーチ・カンパニー・リミテッド シクロプロパンカルボン酸（５－｛５－［ｎ’－（２－クロロ－６－メチルベンゾイル）ヒドラジノカルボニル］－２－メチル－フェニルエチニル｝－ピリジン－２イル）アミドの新規非晶質分散体
UY37695A (es) 2017-04-28 2018-11-30 Novartis Ag Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo
JPWO2018216705A1 (ja) * 2017-05-23 2020-03-26 国立大学法人京都大学 神経変性疾患の予防及び／又は治療剤
WO2018237173A1 (fr) 2017-06-22 2018-12-27 Novartis Ag Molécules d'anticorps dirigées contre cd73 et utilisations correspondantes
WO2019113487A1 (fr) 2017-12-08 2019-06-13 Incyte Corporation Polythérapie à faible dose pour le traitement de néoplasmes myéloprolifératifs
CN111788196A (zh) 2018-01-09 2020-10-16 配体药物公司 缩醛化合物及其治疗用途
CN112312904A (zh) * 2018-04-16 2021-02-02 C4医药公司 螺环化合物
AR126019A1 (es) 2018-05-30 2023-09-06 Novartis Ag Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
KR102618168B1 (ko) * 2018-07-06 2023-12-27 일양약품주식회사 프리온 질환의 예방 또는 치료를 위한 약제학적 조성물
KR102119150B1 (ko) 2018-10-23 2020-06-04 한국원자력의학원 N-1h-벤지미다졸-2-일-3-(1h-피롤-1-일) 벤자미드를 유효성분으로 함유하는 암 예방 또는 치료용 약학적 조성물
US11236070B2 (en) 2019-05-16 2022-02-01 Novartis Ag Chemical process
US11407735B2 (en) 2019-05-16 2022-08-09 Novartis Ag Crystalline forms of N-[4-(Chlorodifluoromethoxy)phenyl]-6-[(3R)-3-hydroxypyrrolidin-1-yl]-5-(1H-pyrazol-5-yl)pyridine-3-carboxamide
GB201913110D0 (en) * 2019-09-11 2019-10-23 Benevolentai Bio Ltd New compounds and methods
EP4031578A1 (fr) 2019-09-18 2022-07-27 Novartis AG Anticorps d'entpd2, polythérapies, et procédés d'utilisation des anticorps et des polythérapies
CN114728943A (zh) * 2020-01-19 2022-07-08 正大天晴药业集团股份有限公司 作为bcr-abl抑制剂的化合物
EP4353230A3 (fr) 2020-01-28 2024-06-19 Teva Pharmaceuticals International GmbH Formes à l'état solide d'asciminib et leur procédé de préparation
WO2021156360A1 (fr) 2020-02-05 2021-08-12 INSERM (Institut National de la Santé et de la Recherche Médicale) Procédés d'interruption d'un traitement avec un inhibiteur de tyrosine kinase (tki)
CN111321200A (zh) * 2020-02-28 2020-06-23 广州安镝声生物医药科技有限公司 一种细胞外abl1激酶活性检测试剂盒及其应用
CN115124551B (zh) * 2021-03-24 2024-04-30 奥锐特药业(天津)有限公司 一种高纯度米哚妥林的制备方法
WO2022206937A1 (fr) * 2021-04-01 2022-10-06 苏州晶云药物科技股份有限公司 Nouvelle forme cristalline de chlorhydrate de composé nicotinamide à substitution par pyrazole et son procédé de préparation
EP4337205A1 (fr) 2021-05-11 2024-03-20 Novartis AG Schémas posologiques
KR20240014478A (ko) 2021-05-28 2024-02-01 치아타이 티안큉 파마수티컬 그룹 주식회사 Bcr-abl 억제제로 사용되는 화합물
CN114149409B (zh) * 2021-11-16 2024-03-22 中国药科大学 一种具有蛋白激酶抑制活性的（杂）芳基酰胺类化合物
CN116135851A (zh) * 2021-11-17 2023-05-19 武汉众诚康健生物医药科技有限公司 一种芳香胺化合物及其应用
WO2023114759A2 (fr) * 2021-12-13 2023-06-22 The Regents Of The University Of California Inhibiteurs d'abl et leurs utilisations
CN115109048B (zh) * 2022-08-10 2023-12-08 中国药科大学 一种(杂)芳基酰胺类化合物
WO2024100212A1 (fr) 2022-11-10 2024-05-16 Synthon B.V. Forme cristalline du chlorhydrate d'asciminib

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH445129A (fr) 1964-04-29 1967-10-15 Nestle Sa Procédé pour la préparation de composés d'inclusion à poids moléculaire élevé
US3459731A (en) 1966-12-16 1969-08-05 Corn Products Co Cyclodextrin polyethers and their production
US3426011A (en) 1967-02-13 1969-02-04 Corn Products Co Cyclodextrins with anionic properties
US3453257A (en) 1967-02-13 1969-07-01 Corn Products Co Cyclodextrin with cationic properties
US3453259A (en) 1967-03-22 1969-07-01 Corn Products Co Cyclodextrin polyol ethers and their oxidation products
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
DE2845997A1 (de) 1978-10-23 1980-04-30 Bayer Ag Pflanzenwachstumsregulierende mittel, verfahren zu ihrer herstellung und ihre verwendung zur regulierung des pflanzenwachstums
US4737323A (en) 1986-02-13 1988-04-12 Liposome Technology, Inc. Liposome extrusion method
US5093330A (en) 1987-06-15 1992-03-03 Ciba-Geigy Corporation Staurosporine derivatives substituted at methylamino nitrogen
EP0333791A1 (fr) 1987-09-23 1989-09-27 Ciba-Geigy Ag Composes heterocycliques
US5010099A (en) 1989-08-11 1991-04-23 Harbor Branch Oceanographic Institution, Inc. Discodermolide compounds, compositions containing same and method of preparation and use
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5395855A (en) 1990-05-07 1995-03-07 Ciba-Geigy Corporation Hydrazones
IL115849A0 (en) 1994-11-03 1996-01-31 Merz & Co Gmbh & Co Tangential filtration preparation of liposomal drugs and liposome product thereof
NZ334821A (en) 1996-08-30 2000-12-22 Novartis Ag Method for producing epothilones
DE69724269T2 (de) 1996-09-06 2004-06-09 Obducat Ab Verfahren für das anisotrope ätzen von strukturen in leitende materialien
DK1367057T3 (da) 1996-11-18 2009-01-19 Biotechnolog Forschung Gmbh Epothiloner E og F
US6441186B1 (en) 1996-12-13 2002-08-27 The Scripps Research Institute Epothilone analogs
GB9721069D0 (en) 1997-10-03 1997-12-03 Pharmacia & Upjohn Spa Polymeric derivatives of camptothecin
US6194181B1 (en) 1998-02-19 2001-02-27 Novartis Ag Fermentative preparation process for and crystal forms of cytostatics
CA2322157C (fr) 1998-02-25 2012-05-29 Sloan-Kettering Institute For Cancer Research Synthese d'epothilones, de leurs intermediaires et de leurs analogues
BR9912938B1 (pt) 1998-08-11 2011-06-28 derivados de isoquinolina, composição que os compreende, processo para preparação e uso dos mesmos.
EP1135470A2 (fr) 1998-11-20 2001-09-26 Kosan Biosciences, Inc. Matieres et procedes recombinants destines a la production d'epothilone et de derives d'epothilone
CA2397493A1 (fr) 2000-01-27 2001-08-02 Cytovia, Inc. Nicotinamides substituees, leurs analogues, activateurs des caspases et inducteurs de l'apoptose et leur emploi
PE20020354A1 (es) 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
WO2003039529A1 (fr) 2001-11-07 2003-05-15 4Sc A.G. Agents antibacteriens selectifs
AU2002367087A1 (en) 2001-12-21 2003-07-15 7Tm Pharma A/S Method for the treatment of mc receptor related disorders with a chelate and/or a chelator
GB0215676D0 (en) * 2002-07-05 2002-08-14 Novartis Ag Organic compounds
US8030336B2 (en) 2002-12-13 2011-10-04 Ym Biosciences Australia Pty Ltd Nicotinamide-based kinase inhibitors
AR043633A1 (es) 2003-03-20 2005-08-03 Schering Corp Ligandos de receptores de canabinoides
US20070054916A1 (en) 2004-10-01 2007-03-08 Amgen Inc. Aryl nitrogen-containing bicyclic compounds and methods of use
US20080167347A1 (en) 2005-01-20 2008-07-10 Shiongi & Co., Ltd. Ctgf Expression Inhibitor
EP1881961A1 (fr) 2005-05-11 2008-01-30 Novo Nordisk A/S Nouveaux composes d'haloalkylsulfone substitues utiles dans le traitement de l'obesite et de diabetes
WO2007002441A1 (fr) 2005-06-24 2007-01-04 Emory University Procedes d'utilisation d'inhibiteurs de tyrosine kinase competitive non atp afin de traiter des infections pathogenes
DK1746097T3 (da) 2005-07-20 2010-05-25 Aventis Pharma Sa 1,4-dihydropyridin-kondenserede heterocykliske ringe, fremgangsmåde til fremstilling af disse, anvendelse og sammensætninger, der indeholder dem
KR20080109068A (ko) * 2006-04-05 2008-12-16 노파르티스 아게 암을 치료하기 위한 ｂｃｒ-ａｂｌ/ｃ-ｋｉｔ/ｐｄｇｆ-ｒ ｔｋ 억제제를 포함하는 조합물
WO2008021725A2 (fr) 2006-08-11 2008-02-21 Smithkline Beecham Corporation Composés chimiques
CA2667010A1 (fr) 2006-10-20 2008-05-02 Irm Llc Compositions et procedes de modulation de recepteurs de c-kit et de facteur de croissance derive de plaquettes (pdgfr)
EP2097380A1 (fr) * 2006-11-15 2009-09-09 High Point Pharmaceuticals, LLC Nouveaux composés substitués d'haloalkylsulfone utilisés pour traiter l'obésité et le diabète
JP5286281B2 (ja) * 2007-01-05 2013-09-11 ブリストル−マイヤーズ スクイブ カンパニー アミノピラゾールキナーゼ阻害剤
WO2008112695A2 (fr) 2007-03-12 2008-09-18 Irm Llc Inhibiteurs de protéine kinase et procédés d'utilisation de ceux-ci
WO2008124393A1 (fr) 2007-04-04 2008-10-16 Irm Llc Derives de benzothiazole et leur utilisation en tant qu'inhibiteurs des proteines kinases
WO2008144253A1 (fr) 2007-05-14 2008-11-27 Irm Llc Inhibiteurs de la protéine kinase et procédé d'utilisation de ceux-ci
BRPI0815038A2 (pt) 2007-08-02 2015-03-17 Hoffmann La Roche Uso de derivados de benzamida para o tratamento de transtornos do cns
WO2009039127A1 (fr) 2007-09-17 2009-03-26 Abbott Laboratories Dérivé d'uracile ou de thymine pour le traitement de l'hépatite c
EA201001847A1 (ru) 2008-06-11 2011-08-30 Айрм Ллк Соединения и композиции, применяемые для лечения малярии
BRPI0920608A2 (pt) 2008-09-29 2019-09-24 Boehringer Ingelheim Int compostos quimicos
CN102548987B (zh) 2009-07-14 2014-04-16 江苏迈度药物研发有限公司 作为激酶抑制剂的氟取代化合物及其使用方法
JP2011057661A (ja) 2009-08-14 2011-03-24 Bayer Cropscience Ag 殺虫性カルボキサミド類
KR101663637B1 (ko) 2009-11-13 2016-10-07 제노스코 키나아제 억제제
JO3634B1 (ar) * 2009-11-17 2020-08-27 Novartis Ag طريقة لعلاج اضطرابات تكاثرية وحالات مرضية أخرى متوسطة بنشاط كيناز bcr-abl، c-kit، ddr1، ddr2، أو pdgf-r
WO2011082400A2 (fr) 2010-01-04 2011-07-07 President And Fellows Of Harvard College Modulateurs du récepteur immunosuppresseur pd-1 et procédés d'utilisation de ceux-ci
SG182361A1 (en) 2010-01-29 2012-08-30 Hanmi Science Co Ltd THIENO[3,2-d]PYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY ON PROTEIN KINASES
US9464065B2 (en) 2011-03-24 2016-10-11 The Scripps Research Institute Compounds and methods for inducing chondrogenesis
CN102276500A (zh) * 2011-05-05 2011-12-14 西安交通大学 水杨酰胺类抗肿瘤化合物及其合成方法和用途
US9278910B2 (en) 2011-05-31 2016-03-08 Receptos, Inc. GLP-1 receptor stabilizers and modulators
JP6080947B2 (ja) 2012-05-15 2017-02-15 ノバルティス アーゲー Ａｂｌ１、ａｂｌ２およびｂｃｒ−ａｂｌ１の活性を阻害するための化合物および組成物
CA2868958C (fr) 2012-05-15 2020-09-01 Novartis Ag Composes et compositions pour inhiber l'activite d'abl1, abl2 et bcr-abl1
MX2014013373A (es) * 2012-05-15 2015-08-14 Novartis Ag Derivados de benzamida para inhibir la actividad de abl1, abl2 y bcr-abl1.
WO2013171642A1 (fr) * 2012-05-15 2013-11-21 Novartis Ag Dérivés de benzamide pour inhiber l'activité d'abl1, d'abl2 et de bcr-abl2

Also Published As

Publication number Publication date
ES2670601T9 (es) 2022-11-30
HUS2200046I1 (hu) 2022-11-28
TWI560183B (en) 2016-12-01
UA113208C2 (xx) 2016-12-26
AR091063A1 (es) 2014-12-30
ZA201407065B (en) 2016-08-31
FR22C1053I1 (fr) 2022-12-16
HUE039138T2 (hu) 2018-12-28
CA2868958A1 (fr) 2013-11-21
CU20140131A7 (es) 2015-04-29
KR20150020170A (ko) 2015-02-25
PE20210667A1 (es) 2021-04-05
IL235566A0 (en) 2015-02-01
US8829195B2 (en) 2014-09-09
ME03095B (fr) 2019-01-20
ES2670601T3 (es) 2018-05-31
WO2013171639A1 (fr) 2013-11-21
RS57177B1 (sr) 2018-07-31
AP2014007992A0 (en) 2014-10-31
BR112014026383A2 (pt) 2017-06-27
EP2861579A1 (fr) 2015-04-22
CY1120235T1 (el) 2019-07-10
PH12014502531A1 (en) 2015-01-12
IL235566A (en) 2016-09-29
SG11201407152XA (en) 2014-11-27
HRP20180695T1 (hr) 2018-06-01
US20130310395A1 (en) 2013-11-21
NL301201I2 (nl) 2022-12-07
AP3613A (en) 2016-02-29
BR112014026383B1 (pt) 2020-11-17
CR20140519A (es) 2015-03-26
MX2014013374A (es) 2015-01-16
SI2861579T1 (en) 2018-05-31
FR22C1053I2 (fr) 2023-11-10
CY2022033I1 (el) 2023-01-05
PT2861579T (pt) 2018-04-27
PH12014502531B1 (en) 2015-01-12
TW201400471A (zh) 2014-01-01
NO2022043I1 (en) 2022-10-25
LTPA2022523I1 (fr) 2022-12-12
UY34811A (es) 2013-12-31
MX359014B (es) 2018-09-12
CL2014002757A1 (es) 2015-01-23
PE20161416A1 (es) 2017-01-08
CA2868958C (fr) 2020-09-01
PL2861579T3 (pl) 2018-07-31
EP2861579B9 (fr) 2018-08-29
NZ701626A (en) 2016-02-26
MA37519B1 (fr) 2017-03-31
AU2013261127A1 (en) 2014-11-20
CN104302638B (zh) 2016-08-24
GT201400253A (es) 2017-09-28
US20140343086A1 (en) 2014-11-20
DK2861579T3 (en) 2018-05-28
JP6078639B2 (ja) 2017-02-08
DOP2014000256A (es) 2015-02-27
AU2013261127B2 (en) 2015-03-12
TN2014000427A1 (en) 2016-03-30
PE20150669A1 (es) 2015-05-17
TR201807023T4 (tr) 2018-06-21
GEP201606532B (en) 2016-08-25
EP2861579B1 (fr) 2018-02-21
MY169377A (en) 2019-03-26
LT2861579T (lt) 2018-05-10
CN104302638A (zh) 2015-01-21
CY2022033I2 (el) 2023-01-05
SV2014004850A (es) 2018-04-04
EA024391B1 (ru) 2016-09-30
DK2861579T5 (da) 2022-10-24
CU24265B1 (es) 2017-07-04
HK1203495A1 (en) 2015-10-30
CO7131380A2 (es) 2014-12-01
KR102091893B1 (ko) 2020-03-23
JP2015521185A (ja) 2015-07-27
JO3453B1 (ar) 2020-07-05
EA201491824A1 (ru) 2015-02-27

Similar Documents

Publication Publication Date Title
MA37519A1 (fr) Composés et compositions pour inhiber l'activité d'abl1, abl2 et bcr-abl1
MA35926B1 (fr) Pyrrolidine-2-carboxamides substitués
MA35089B1 (fr) Inhibiteurs de la production de leucotrienes de type benzodioxane
MA35357B1 (fr) Composes de type anilines
MA35086B1 (fr) Compose de triazolopyridine
MA35819B1 (fr) Composés hétéroaryl pyridones et aza-pyridones en tant qu'inhibiteurs de l'activité btk
HRP20090235B1 (hr) Karbonilirani (aza) cikloheksani kao ligandi dopaminskog receptora d
MA37142A3 (fr) Dérivés de dihydro-benzo-oxazine et de dihydro-pyrido-oxazine
MA33492B1 (fr) Inhibiteurs de bace
NZ716420A (en) Fused heterocyclic compounds as sodium channel modulators
MA35049B1 (fr) Triazolopyridines
MA32351B1 (fr) Derives d'aminodihydrothiazine a titre d'inhibiteurs de bace pour le traitement de la maladie d'alzheimer
EA201490493A1 (ru) Пирано[3,2-d][1,3]тиазол в качестве ингибиторов гликозидазы
EA201490272A1 (ru) Новые 4-пиперидинильные соединения для применения в качестве ингибиторов танкиразы
MA38645B1 (fr) Nouveaux inhibiteurs de cyp17/antiandrogènes
SG195319A1 (en) Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors
MA37990B1 (fr) Benzamides
MA35893B1 (fr) Dérivés d'amide hétérocyclique comme antagonistes du récepteur p2x7
MA37943B1 (fr) 2-oxo-2,3-dihydro-indoles destinés au traitement de troubles du snc
IN2014DN07082A (fr)
MA38410B1 (fr) Composés d'azétidinyloxyphénylpyrrolidine
MA35742B1 (fr) Dérivés de n- (4 -quinolinylmethyl) sulfonamide et leur utilisation en tant qu'antihelminthiques
MA38857A1 (fr) Dérivés de 1-(pipérazin-1-yl)-2-([1,2,4]triazol-1-yl)-éthanone
MA20150280A2 (fr) Dérivés d'aryléthynyle
MA38010B1 (fr) Dérivés d'éthynyl utilisés en tant que modulateurs de l'activité des récepteurs mglur5